

Breast Cancer

A study to compare “ipatasertib + chemotherapy” with “placebo + chemotherapy” – in patients with inoperable or metastatic triple negative breast cancer

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

Trial Status
Completed

Trial Runs In
8 Countries

Trial Identifier
NCT02162719 2014-000469-35
GO29227

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, randomized, double-blind study will estimate the efficacy, safety and tolerability of ipatasertib combined with paclitaxel compared with placebo combined with paclitaxel in participants with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC), as measured by progression-free survival (PFS) in all participants and in participants with phosphatase and tensin homolog (PTEN)-low tumors.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT02162719 2014-000469-35 GO29227
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
≥18 Years

Healthy Volunteers
No

This clinical trial was done to study a new medicine called, “ipatasertib”, for the treatment of patients with “triple negative breast cancer” or “TNBC” for short. This study was done to find out if adding ipatasertib to chemotherapy improved the outcome for patients with TNBC. Researchers also wanted to know the effect of ipatasertib on patients with TNBC who had certain genetic mutations. One hundred and twenty-four patients took part in this study at 69 study centers in eight countries.